Loading data for NAMSW — first visit, this takes a few seconds.
NewAmsterdam Pharma N.V. (NAMSW)
NasdaqGM: NAMSW
· Real-Time Price · USD
16.00
+0.00 (0.00%)
At close: Aug 18, 2026, 2:21 PM
NewAmsterdam Pharma N.V. (NAMSW) Stock Price, Analysis & Data
0.00% (1D)
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 7.12M |
| Net Income (ttm) | -259.5M |
| Beta | 0.11 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 2.98 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 15,005 |
| Avg. Volume (20D) | 1,246 |
| Open | 24.41 |
| Previous Close | 16.00 |
| Day's Range | 15.98 - 16.00 |
| 52-Week Range | 12.67 - 30.45 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NAMSW
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is ...
Full Company ProfileFinancial Performance
In 2025, NewAmsterdam Pharma's revenue was 22.5M, a decrease of -50.61% compared to the previous year's 45.56M. Earnings were -203.82M, a decrease of -15.64%.
Financial Statements